Royal Philips Electronics (NYSE:PHG) is adding a robotic system to its treatment options for clogged heart arteries in a new pact with Natick, Mass.-based Corindus Inc.
Philips inks deal with Mass. vascular robots firm
Neuralstem Inc.
Neuros Medical touts pain-blocking device study | Research roundup
Neurotechnology startup Neuros Medical Inc. reported encouraging results from the first in-human study of its device that blocks pain for amputees.
The Willoughby, Ohio-based company said that four of five patients in the study reported that its device reduced their pain to “zero,” according to a statement from the company.
Neuralstem settles IP suit with ReNeuron
Neuralstem Inc. (AMEX:CUR) reached a settlement in its intellectual property lawsuit against ReNeuron Ltd.
The deal closed the litigation between the two companies that began in April 2008, when Neuralstem sued ReNeuron over the alleged theft of trade secrets related to its central nervous system stem cell technology.
Neuralstem aims to treat paralysis in spinal injury stem cell trial
Neuralstem Inc. (AMEX:CUR) asked the Food & Drug Administration for permission to begin a clinical trial of a chronic spinal injury treatment using stem cells.
The Rockville, Md.-based company’s Phase I clinical safety trial would employ its adult stem cell technology with cells derived from spinal cords to treat 16 patients with American Spinal Injury Assn. Grade A level of impairment, or complete paralysis, one to two years after the injury that caused their condition.
